Liabilities / Assets
98th percentile
Higher debt load relative to assets than 98% of similar nonprofits.
Oxfendazole Development Group
990 • Fiscal year 2018 • EIN 81-1547477
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
3.51x
Liabilities / Revenue
97th percentile
Higher debt load relative to revenue than 97% of similar nonprofits.
Net Margin
8th percentile
Higher net margin than 8% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
9th percentile
Faster asset growth than 9% of similar nonprofits.
Revenue Growth
2nd percentile
Faster revenue growth than 2% of similar nonprofits.
Balance Sheet
Assets
Down$4,995
Down $4,771 (-49%) from 2017
Net Assets
Down-$12,532
Down $4,772 (-61%) from 2017
Liabilities
Flat$17,527
Flat from 2017
Revenue And Expenses
Revenue
Down$9,233
Down $88,420 (-91%) from 2017
Expenses
Down$14,004
Down $78,117 (-85%) from 2017
Net Income
Down-$4,771
Down $10,303 (-186%) from 2017
Historical Trend
Filing Detail Status
This 2018 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2018 to Dec 31, 2018
Mission and Program Overview
Mission
The Oxfendazole Development Group is a 501c3 nonprofit organization formed and operated exclusively for charitable purposes specifically for the purpose of engaging in research and development of pharmaceutical treatments to help eliminate neglected tropical diseases NTDs and to facilitate access to such treatments for individuals in need.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2018 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $4,995
- Liabilities
- $17,527
- Net assets
- -$12,532
- Revenue
- $9,233
- Expenses
- $14,004
- Net income
- -$4,771